2.85
  Price58.33%   +1.05
(After Hours: 2.84 -0.0100 -0.35%)
Jun-24-22 11:21AM Penny Stocks To Buy Now? 4 Biotech Stocks To Watch Before July 2022PennyStocks
Jun-21-22 01:35AM Best Penny Stocks to Buy This Week? 3 to Watch as June Ends PennyStocks
12:18PM Why Clovis Oncology Stock Is Blasting Off TodayThe Motley Fool
Jun-17-22 08:04AM 3 Biotech Penny Stocks That Climbed in After-Hours TradingPennyStocks
Jun-16-22 04:20AM Clovis (CLVS) Up 19.4% on Upbeat Data From Solid Tumor StudyZacks Investment Research
Jun-15-22 04:52AM Best Penny Stocks To Buy Now? 4 To Watch After June’s Fed MeetingPennyStocks
Jun-14-22 07:00AM What to Know About Trading Penny Stocks on June 14th PennyStocks
Jun-06-22 09:47AM Penny Stocks To Buy Now? 4 To Watch With Big NewsPennyStocks
Jun-03-22 11:31AM Why Is Clovis (CLVS) Down 55.2% Since Last Earnings Report?Zacks Investment Research
May-16-22 08:30AM 2 Biotech Stocks That Could Go ParabolicThe Motley Fool
May-09-22 11:09AM Viatris' (VTRS) Q1 Earnings Beat, Revenues Miss EstimatesZacks Investment Research
11:05AM Alcon (ALC) to Report Q1 Earnings: What's in the Cards?Zacks Investment Research
May-06-22 01:23AM Endo (ENDP) Beats on Q1 Earnings, Guides Weak Q2 ResultsZacks Investment Research
10:56AM STERIS (STE) to Report Q4 Earnings: What's in the Cards?Zacks Investment Research
May-06-22 07:12AM Why Clovis Oncology Stock Was Plummeting This WeekThe Motley Fool
May-05-22 10:22AM Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues LagZacks Investment Research
May-04-22 02:21AM Clovis (CLVS) Q1 Loss Wider than Expected, Revenues MissZacks Investment Research
09:15AM Clovis Oncology (CLVS) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research
Apr-27-22 03:03AM Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research
Apr-18-22 04:51AM Why Clovis Oncology Stock Fell 10.5% on MondayThe Motley Fool
Apr-05-22 05:33AM Best Penny Stocks to Watch After the Stock Market Takes a Bear TurnPennyStocks
Apr-04-22 03:11AM Clovis (CLVS) Up 24% on Upbeat Data From Ovarian Cancer StudyZacks Investment Research
Apr-03-22 05:30AM Trading Penny Stocks & What You Need to Know in April PennyStocks
Apr-01-22 11:03AM Top Penny Stocks To Buy Under $5? 4 Short Squeeze Stocks To Watch NowPennyStocks
Mar-31-22 04:41AM Why Clovis Oncology Stock Skyrocketed 80% This WeekThe Motley Fool
09:25AM Trading Penny Stocks? Top Stock Market News for March 31st, 2022PennyStocks
Mar-31-22 08:14AM The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 ShortfallBenzinga
Mar-25-22 11:30AM Why Is Clovis (CLVS) Down 14.8% Since Last Earnings Report?Zacks Investment Research
Mar-17-22 01:15AM AstraZeneca, Merck's Lynparza Cut Risk of Breast Cancer DeathZacks Investment Research
Mar-14-22 10:34AM AstraZeneca, Merck's Lynparza Gets FDA Nod for Expanded UseZacks Investment Research
Mar-12-22 12:30PM Hot Penny Stocks to Watch Next Week? 3 For Your ListPennyStocks
Feb-24-22 02:49AM Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues LagZacks Investment Research
Feb-22-22 12:01PM Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & MoreZacks Investment Research
Jan-19-22 10:15AM 2 Cancer Stocks With Absurdly Low ValuationsThe Motley Fool
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company's product candidates include lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors; and rociletinib, an oral mutant-selective inhibitor of epidermal growth factor receptor. It distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; collaboration and license agreement with Les Laboratoires Servier; a clinical collaboration with Bristol-Myers Squibb Company; a partnership with Foundation Medicine, Inc; and a diagnostic collaboration with Myriad Genetics, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Cap:    |  Volume (24h):